Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma
Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with os...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 1992-03, Vol.10 (3), p.459-463 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 463 |
|---|---|
| container_issue | 3 |
| container_start_page | 459 |
| container_title | Journal of clinical oncology |
| container_volume | 10 |
| creator | E R Ellis R B Marcus, Jr M J Cicale D S Springfield F J Bova J Graham-Pole W F Enneking S S Spanier R R Million |
| description | Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x-rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter.
At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period.
Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment. |
| doi_str_mv | 10.1200/JCO.1992.10.3.459 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16324821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16324821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-11ad31dbca46d3c1f63ec99f1316516fb1fd9c066945c5cb11b287de1f07ff123</originalsourceid><addsrcrecordid>eNpFkMtqGzEUhkVJSZ20D9BFQYsku3F1pJFmZllMeiOQLlroTmh0sRU0kivN4PbtK9cmhQMHzn8R-hB6C2QNlJD3XzePaxgGuq4Htm758AKtgNOu6TrOL9CKdIw20LOfr9BVKU-EQNszfokuoWuJ6NsV8t-WMKWo8h_slqhnnyKebZkLVm62GR92KdgmLHGLfc7KePXPoqLBJv1OeRm99hHX2VfFxho8-HmHU5lt2troNS4q6zSp1-ilU6HYN-d9jX58vP---dw8PH76svnw0GjWi7kBUIaBGbVqhWEanGBWD4MDBoKDcCM4M2gixNByzfUIMNK-MxYc6ZwDyq7R3al3n9OvpX5FTr5oG4KKNi1FgmC07SlUI5yMOqdSsnVyn_1USUgg8ohXVrzyiPd4YLLirZl35_JlnKz5nzjxrPrNWVdFq-CyitqXZxunA6XkWHN7su38dnfw2coyqRBqKZVPOj0_9xfKL5Hy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16324821</pqid></control><display><type>article</type><title>Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Journals@Ovid Ovid Autoload</source><creator>E R Ellis ; R B Marcus, Jr ; M J Cicale ; D S Springfield ; F J Bova ; J Graham-Pole ; W F Enneking ; S S Spanier ; R R Million</creator><creatorcontrib>E R Ellis ; R B Marcus, Jr ; M J Cicale ; D S Springfield ; F J Bova ; J Graham-Pole ; W F Enneking ; S S Spanier ; R R Million</creatorcontrib><description>Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x-rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter.
At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period.
Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.1992.10.3.459</identifier><identifier>PMID: 1740684</identifier><language>eng</language><publisher>Baltimore, MD: American Society of Clinical Oncology</publisher><subject>Adolescent ; Adult ; Antineoplastic agents ; Biological and medical sciences ; Child ; Combined Modality Therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Doxorubicin - therapeutic use ; Female ; Humans ; Lung - physiopathology ; Lung - radiation effects ; Male ; Medical sciences ; Middle Aged ; Osteosarcoma - drug therapy ; Osteosarcoma - radiotherapy ; Pharmacology. Drug treatments ; Prospective Studies ; Radiotherapy - adverse effects ; Radiotherapy - methods ; Respiratory Function Tests</subject><ispartof>Journal of clinical oncology, 1992-03, Vol.10 (3), p.459-463</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-11ad31dbca46d3c1f63ec99f1316516fb1fd9c066945c5cb11b287de1f07ff123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,778,782,787,788,3718,23917,23918,25127,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5292209$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1740684$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>E R Ellis</creatorcontrib><creatorcontrib>R B Marcus, Jr</creatorcontrib><creatorcontrib>M J Cicale</creatorcontrib><creatorcontrib>D S Springfield</creatorcontrib><creatorcontrib>F J Bova</creatorcontrib><creatorcontrib>J Graham-Pole</creatorcontrib><creatorcontrib>W F Enneking</creatorcontrib><creatorcontrib>S S Spanier</creatorcontrib><creatorcontrib>R R Million</creatorcontrib><title>Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x-rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter.
At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period.
Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Combined Modality Therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Lung - physiopathology</subject><subject>Lung - radiation effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - radiotherapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Radiotherapy - adverse effects</subject><subject>Radiotherapy - methods</subject><subject>Respiratory Function Tests</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtqGzEUhkVJSZ20D9BFQYsku3F1pJFmZllMeiOQLlroTmh0sRU0kivN4PbtK9cmhQMHzn8R-hB6C2QNlJD3XzePaxgGuq4Htm758AKtgNOu6TrOL9CKdIw20LOfr9BVKU-EQNszfokuoWuJ6NsV8t-WMKWo8h_slqhnnyKebZkLVm62GR92KdgmLHGLfc7KePXPoqLBJv1OeRm99hHX2VfFxho8-HmHU5lt2troNS4q6zSp1-ilU6HYN-d9jX58vP---dw8PH76svnw0GjWi7kBUIaBGbVqhWEanGBWD4MDBoKDcCM4M2gixNByzfUIMNK-MxYc6ZwDyq7R3al3n9OvpX5FTr5oG4KKNi1FgmC07SlUI5yMOqdSsnVyn_1USUgg8ohXVrzyiPd4YLLirZl35_JlnKz5nzjxrPrNWVdFq-CyitqXZxunA6XkWHN7su38dnfw2coyqRBqKZVPOj0_9xfKL5Hy</recordid><startdate>19920301</startdate><enddate>19920301</enddate><creator>E R Ellis</creator><creator>R B Marcus, Jr</creator><creator>M J Cicale</creator><creator>D S Springfield</creator><creator>F J Bova</creator><creator>J Graham-Pole</creator><creator>W F Enneking</creator><creator>S S Spanier</creator><creator>R R Million</creator><general>American Society of Clinical Oncology</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19920301</creationdate><title>Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma</title><author>E R Ellis ; R B Marcus, Jr ; M J Cicale ; D S Springfield ; F J Bova ; J Graham-Pole ; W F Enneking ; S S Spanier ; R R Million</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-11ad31dbca46d3c1f63ec99f1316516fb1fd9c066945c5cb11b287de1f07ff123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Combined Modality Therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Lung - physiopathology</topic><topic>Lung - radiation effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - radiotherapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Radiotherapy - adverse effects</topic><topic>Radiotherapy - methods</topic><topic>Respiratory Function Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>E R Ellis</creatorcontrib><creatorcontrib>R B Marcus, Jr</creatorcontrib><creatorcontrib>M J Cicale</creatorcontrib><creatorcontrib>D S Springfield</creatorcontrib><creatorcontrib>F J Bova</creatorcontrib><creatorcontrib>J Graham-Pole</creatorcontrib><creatorcontrib>W F Enneking</creatorcontrib><creatorcontrib>S S Spanier</creatorcontrib><creatorcontrib>R R Million</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>E R Ellis</au><au>R B Marcus, Jr</au><au>M J Cicale</au><au>D S Springfield</au><au>F J Bova</au><au>J Graham-Pole</au><au>W F Enneking</au><au>S S Spanier</au><au>R R Million</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>1992-03-01</date><risdate>1992</risdate><volume>10</volume><issue>3</issue><spage>459</spage><epage>463</epage><pages>459-463</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Because of the scarcity of information regarding long-term follow-up of pulmonary function after whole-lung irradiation, a prospective study was started at the University of Florida in 1979 to evaluate pulmonary function after treatment with whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma.
Between 1979 and 1984, 57 osteogenic sarcoma patients with no evidence of metastatic disease at diagnosis received adjuvant therapy consisting of whole-lung irradiation (with the heart shielded) followed by Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH). The whole-lung irradiation schema was 1,600 cGy in 10 fractions with 8-MV x-rays via anterior and posterior fields. This was followed by five cycles of Adriamycin for a total dose of 450 mg/m2. Pulmonary function tests (PFTs) consisting of spirometry, lung volumes, and diffusing capacity were obtained before the whole-lung irradiation, at 6 and 12 months after irradiation, and at yearly intervals thereafter.
At the time of analysis, 28 of the 57 patients were available for study, with a mean follow-up of 42 months (range, 6 to 77 months). Follow-up pulmonary function testing revealed decreased forced vital capacity (FVC) and forced expiratory volume at 1 second (FEV1) during the first 6 to 12 months after whole-lung irradiation. These values returned to baseline during the second-year posttherapy and remained at baseline throughout the remainder of the follow-up period. Changes in lung volumes demonstrated a similar early trend, with significant decreases in total lung capacity (TLC) and functional residual capacity (FRC) at 6 to 12 months. These changes, however, did not improve significantly during the remainder of the follow-up period. Diffusing capacity of the lungs for carbon monoxide (DLCO) also reached a nadir at 6 to 12 months after whole-lung irradiation, with resolution by 2 years and maintenance of at least baseline values for the remainder of the follow-up period.
Treatment with whole-lung irradiation and Adriamycin, as given in this study, caused no significant sequelae, as demonstrated by pulmonary function testing during the mean follow-up period of 42 months, although a mild, transient restrictive ventilatory defect occurred at 6 to 12 months after treatment.</abstract><cop>Baltimore, MD</cop><pub>American Society of Clinical Oncology</pub><pmid>1740684</pmid><doi>10.1200/JCO.1992.10.3.459</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 1992-03, Vol.10 (3), p.459-463 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_16324821 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Journals@Ovid Ovid Autoload |
| subjects | Adolescent Adult Antineoplastic agents Biological and medical sciences Child Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Doxorubicin - therapeutic use Female Humans Lung - physiopathology Lung - radiation effects Male Medical sciences Middle Aged Osteosarcoma - drug therapy Osteosarcoma - radiotherapy Pharmacology. Drug treatments Prospective Studies Radiotherapy - adverse effects Radiotherapy - methods Respiratory Function Tests |
| title | Pulmonary function tests after whole-lung irradiation and doxorubicin in patients with osteogenic sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A04%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pulmonary%20function%20tests%20after%20whole-lung%20irradiation%20and%20doxorubicin%20in%20patients%20with%20osteogenic%20sarcoma&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=E%20R%20Ellis&rft.date=1992-03-01&rft.volume=10&rft.issue=3&rft.spage=459&rft.epage=463&rft.pages=459-463&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.1992.10.3.459&rft_dat=%3Cproquest_cross%3E16324821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16324821&rft_id=info:pmid/1740684&rfr_iscdi=true |